Could a One-Time immune cell infusion help older leukemia patients avoid harsh chemo?

NCT ID NCT05707273

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infuse them back. The goal is to see if this approach is safe and feasible as a consolidation treatment, potentially offering a gentler alternative to standard chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD19-CAR T cells (a patient's own immune cells modified to attack cancer)
What this could lead to
If it works, this could offer a less toxic treatment option for older adults with leukemia, potentially reducing the need for intensive chemotherapy.
What could go wrong
This is a very early (phase 1) and small (18 participants) trial focused on safety and dosing. CAR T-cell therapy can cause serious side effects like cytokine release syndrome. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.